Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Drugs and Chemicals›Thyrotropin-Releasing Hormone
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Thyrotropin-Releasing Hormone

Drugs and Chemicals · NLM MeSH · updated 2026-10-31 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 5 min read

A tripeptide that stimulates the release of thyrotropin and prolactin.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (908 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A tripeptide that stimulates the release of thyrotropin and prolactin. It is synthesized by the neurons in the paraventricular nucleus of the hypothalamus. After being released into the pituitary portal circulation, TRH (was called TRF) stimulates the release of TSH and PRL from the anterior pituitary gland.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Thyrotropin Releasing Hormone; Protirelin; Thyrotropin-Releasing Factor; Thyrotropin Releasing Factor; Relefact TRH; TRH, Relefact; Thypinone; Protirelin Tartrate (1:1).

Where it fits in the MeSH classification

Broader topics
Pituitary Hormone-Releasing Hormones; Oligopeptides; Neuropeptides
See also
Receptors, Thyrotropin-Releasing Hormone

Related concepts

  • Thyrotropin
  • Prolactin
  • Paraventricular Nucleus
  • Hypothalamus
  • Anterior Pituitary Gland

Research landscape

PubMed indexes 12,941 records tagged with the MeSH heading “Thyrotropin-Releasing Hormone” (counts retrieved 2026-10-31). 154 of them (1.2%) were published from 2020 onward, and the busiest period so far is through 1999 with 11,429 records.

Reviews account for 921 records (7.1%) and meta-analyses for 5. Randomized controlled trials number 169 (1.3%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 11,429 records; 2000-2009: 983 records; 2010-2019: 375 records; 2020 onward: 154 records11,429through 19999832000-20093752010-20191542020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 199911,429
2000-2009983
2010-2019375
2020 onward154
Share of records by publication typeReviews: 7.1 percent; Meta-analyses: 0.0 percent; Randomized controlled trials: 1.3 percentReviews7.1% (921)Meta-analyses0.0% (5)Randomized controlled trials1.3% (169)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 12,941 PubMed records
TypeRecordsShare
Reviews9217.1%
Meta-analyses50.0%
Randomized controlled trials1691.3%

Method: PubMed query "Thyrotropin-Releasing Hormone"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in drugs and chemicals

Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Thyrotropin-releasing hormone (TRH) promotes wound re-epithelialisation in frog and human skin
Meier NT, Haslam IS, Pattwell DM, Zhang GY, Emelianov V, Paredes R, et al.
2013Research article
Design not recorded in structured metadata
38cc by
PMID 24023889 · DOI · PMC3759422
TRH site-specific methylation in oral and oropharyngeal squamous cell carcinoma
Puttipanyalears C, Arayataweegool A, Chalertpet K, Rattanachayoto P, Mahattanasakul P, Tangjaturonsasme N, et al.
2018Research article
Design not recorded in structured metadata
25cc by
PMID 30081853 · DOI · PMC6080527
GATA2 mediates thyrotropin-releasing hormone-induced transcriptional activation of the thyrotropin β gene
Ohba K, Sasaki S, Matsushita A, Iwaki H, Matsunaga H, Suzuki S, et al.
2011Research article
Design not recorded in structured metadata
24cc by
PMID 21533184 · DOI · PMC3077393
Thyrotropin-releasing hormone neurons of different hypothalamic nuclei increase energy expenditure
Constantinescu A, Chandrasekar A, Kleindienst L, Höhne L, Da Silva Lima N, Richter M, et al.
2026Research article
Design not recorded in structured metadata
0cc by
PMID 41980928 · DOI · PMC13083850

Thyrotropin-releasing hormone (TRH) promotes wound re-epithelialisation in frog and human skin [1]

Research article Meier NT, Haslam IS, Pattwell DM, Zhang GY, Emelianov V, Paredes R, et al. · · 2013 · cited 38 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
There remains a critical need for new therapeutics that promote wound healing in patients suffering from chronic skin wounds.
Closing excerpt
These complementary frog and human skin ex vivo assays encourage a comparative biology approach in future wound healing research so as to facilitate the rapid identification and preclinical testing of novel, evolutionarily conserved, and clinically relevant wound healing promoters.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (216 words)

There remains a critical need for new therapeutics that promote wound healing in patients suffering from chronic skin wounds. This is, in part, due to a shortage of simple, physiologically and clinically relevant test systems for investigating candidate agents. The skin of amphibians possesses a remarkable regenerative capacity, which remains insufficiently explored for clinical purposes. Combining comparative biology with a translational medicine approach, we report the development and application of a simple ex vivo frog (Xenopus tropicalis) skin organ culture system that permits exploration of the effects of amphibian skin-derived agents on re-epithelialisation in both frog and human skin. Using this amphibian model, we identify thyrotropin-releasing hormone (TRH) as a novel stimulant of epidermal regeneration. Moving to a complementary human ex vivo wounded skin assay, we demonstrate that the effects of TRH are conserved across the amphibian-mammalian divide: TRH stimulates wound closure and formation of neo-epidermis in organ-cultured human skin, accompanied by increased keratinocyte proliferation and wound healing-associated differentiation (cytokeratin 6 expression). Thus, TRH represents a novel, clinically relevant neuroendocrine wound repair promoter that deserves further exploration. These complementary frog and human skin ex vivo assays encourage a comparative biology approach in future wound healing research so as to facilitate the rapid identification and preclinical testing of novel, evolutionarily conserved, and clinically relevant wound healing promoters.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 24023889 · DOI · PMC3759422

TRH site-specific methylation in oral and oropharyngeal squamous cell carcinoma [2]

Research article Puttipanyalears C, Arayataweegool A, Chalertpet K, Rattanachayoto P, Mahattanasakul P, Tangjaturonsasme N, et al. · · 2018 · cited 25 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundThe incidence of oral squamous cell carcinoma (OSCC) continues to increase each year.
Closing excerpt
Screening of epithelial cells using real-time PCR showed that the DNA methylation level was significantly higher in oral swab and rinse samples collected from OSCC and oropharyngeal SCC subjects than those from healthy controls (p ConclusionWe demonstrated cg01009664 of TRH as a potential biomarker for OSCC and oropharyngeal SCC screening using oral rinse and swab techniques.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (300 words)

BackgroundThe incidence of oral squamous cell carcinoma (OSCC) continues to increase each year. Clinical examination and biopsy usually detect OSCC at an advanced stage that is difficult to treat, leading to poor prognosis. DNA methylation pattern is tissue specific and has emerged as a biomarker for the detection of cancers of tissue origin. Herein, we aimed to discover a novel site-specific methylation marker for OSCC.MethodsWe selected OSCC datasets analyzed using the IlluminaHumanMethylation27 BeadChip from the Gene Expression Omnibus repository of the National Center for Biotechnology Information using a bioinformatics approach. From 27,578 CG dinucleotide (CpG) sites, the CpG site with the highest difference in methylation level between healthy and cancerous cells was selected for further validation. A total of 18 mucosal tissue samples were collected from nine healthy controls and nine from OSCC subjects and subjected to microdissection for cell purification, followed by DNA extraction, bisulfite conversion, and pyrosequencing. Additionally, epithelial cells were collected from 2 cohorts including oral rinse from healthy controls, oral rinse and oral swab from OSCC subjects and oral rinse from oropharyngeal squamous cell carcinoma (SCC) were examined for their methylation status using real-time polymerase chain reaction (PCR).ResultsAmong the 27,578 differentially methylated CpG sites, cg01009664 of the thyrotropin-releasing hormone (TRH) gene showed the greatest difference in methylation level between healthy and cancerous cells. Validation of the TRH gene using pyrosequencing revealed a methylation percentage of 7% ± 3.43% in healthy cells in contrast to 63% ± 19.81% in cancerous cells. Screening of epithelial cells using real-time PCR showed that the DNA methylation level was significantly higher in oral swab and rinse samples collected from OSCC and oropharyngeal SCC subjects than those from healthy controls (p ConclusionWe demonstrated cg01009664 of TRH as a potential biomarker for OSCC and oropharyngeal SCC screening using oral rinse and swab techniques.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 30081853 · DOI · PMC6080527

GATA2 mediates thyrotropin-releasing hormone-induced transcriptional activation of the thyrotropin β gene [3]

Research article Ohba K, Sasaki S, Matsushita A, Iwaki H, Matsunaga H, Suzuki S, et al. · · 2011 · cited 24 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Thyrotropin-releasing hormone (TRH) activates not only the secretion of thyrotropin (TSH) but also the transcription of TSHβ and α-glycoprotein (αGSU) subunit genes.
Closing excerpt
These results indicate that GATA2 is the principal mediator of the TRH signaling pathway in TSHβ expression.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (249 words)

Thyrotropin-releasing hormone (TRH) activates not only the secretion of thyrotropin (TSH) but also the transcription of TSHβ and α-glycoprotein (αGSU) subunit genes. TSHβ expression is maintained by two transcription factors, Pit1 and GATA2, and is negatively regulated by thyroid hormone (T3). Our prior studies suggest that the main activator of the TSHβ gene is GATA2, not Pit1 or unliganded T3 receptor (TR). In previous studies on the mechanism of TRH-induced activation of the TSHβ gene, the involvements of Pit1 and TR have been investigated, but the role of GATA2 has not been clarified. Using kidney-derived CV1 cells and pituitary-derived GH3 and TαT1 cells, we demonstrate here that TRH signaling enhances GATA2-dependent activation of the TSHβ promoter and that TRH-induced activity is abolished by amino acid substitution in the GATA2-Zn finger domain or mutation of GATA-responsive element in the TSHβ gene. In CV1 cells transfected with TRH receptor expression plasmid, GATA2-dependent transactivation of αGSU and endothelin-1 promoters was enhanced by TRH. In the gel shift assay, TRH signal potentiated the DNA-binding capacity of GATA2. While inhibition by T3 is dominant over TRH-induced activation, unliganded TR or the putative negative T3-responsive element are not required for TRH-induced stimulation. Studies using GH3 cells showed that TRH-induced activity of the TSHβ promoter depends on protein kinase C but not the mitogen-activated protein kinase, suggesting that the signaling pathway is different from that in the prolactin gene. These results indicate that GATA2 is the principal mediator of the TRH signaling pathway in TSHβ expression.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 21533184 · DOI · PMC3077393

Thyrotropin-releasing hormone neurons of different hypothalamic nuclei increase energy expenditure [4]

Research article Constantinescu A, Chandrasekar A, Kleindienst L, Höhne L, Da Silva Lima N, Richter M, et al. · · 2026

Abstract reading summary — source excerpts
Opening excerpt
Several neuronal populations in the hypothalamus and brainstem express thyrotropin-releasing hormone (TRH).
Closing excerpt
These effects were independent of the thyroid axis, demonstrating that TRH neurons have distinct, subtype-specific ways to increase energy expenditure beyond regulating the thyroid axis in mice.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (143 words)

Several neuronal populations in the hypothalamus and brainstem express thyrotropin-releasing hormone (TRH). While TRH neurons in the paraventricular nucleus (PVN) regulate the thyroid axis, the roles of other TRH-producing neurons remain largely unknown. Here we investigate the role of TRH neurons in the PVN, the dorsomedial hypothalamus (DMH), the medial preoptic area (MPA), and the rostral raphe pallidus (RPa) for metabolism in mice. Selective activation of these populations using chemogenetics in mice revealed that TRH neurons of the hypothalamus increase food intake and influence energy homeostasis in different ways. Specifically, TRH neurons in the PVN and DMH enhance brown adipose tissue activity via a polysynaptic circuit, while MPA-located neurons increase locomotor activity and maintain cold tolerance. These effects were independent of the thyroid axis, demonstrating that TRH neurons have distinct, subtype-specific ways to increase energy expenditure beyond regulating the thyroid axis in mice.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41980928 · DOI · PMC13083850

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Thyroid function in critically ill patients [5]
    Fliers E, Bianco AC, Langouche L, Boelen A · Lancet Diabetes Endocrinol · 2015 · cited 284 times (Europe PMC)
  • Research article Thyrotropin-releasing hormone [6]
    Jackson IM · N Engl J Med · 1982 · cited 256 times (Europe PMC)
  • Research article The TRH neuron: a hypothalamic integrator of energy metabolism [7]
    Lechan RM, Fekete C · Prog Brain Res · 2006 · cited 245 times (Europe PMC)
  • Research article Central regulation of hypothalamic-pituitary-thyroid axis under physiological and pathophysiological conditions [8]
    Fekete C, Lechan RM · Endocr Rev · 2014 · cited 243 times (Europe PMC)
  • Research article The neuroendocrine control of appetite: the role of the endogenous opiates, cholecystokinin, TRH, gamma-amino-butyric-acid and the diazepam receptor [9]
    Morley JE · Life Sci · 1980 · cited 239 times (Europe PMC)
  • Research article Minireview: Thyrotropin-releasing hormone and the thyroid hormone feedback mechanism [10]
    Chiamolera MI, Wondisford FE · Endocrinology · 2009 · cited 215 times (Europe PMC)

References

  1. Meier NT, Haslam IS, Pattwell DM, Zhang GY, Emelianov V, Paredes R, et al.. Thyrotropin-releasing hormone (TRH) promotes wound re-epithelialisation in frog and human skin. . 2013. PMID 24023889 · DOI · PMC3759422
  2. Puttipanyalears C, Arayataweegool A, Chalertpet K, Rattanachayoto P, Mahattanasakul P, Tangjaturonsasme N, et al.. TRH site-specific methylation in oral and oropharyngeal squamous cell carcinoma. . 2018. PMID 30081853 · DOI · PMC6080527
  3. Ohba K, Sasaki S, Matsushita A, Iwaki H, Matsunaga H, Suzuki S, et al.. GATA2 mediates thyrotropin-releasing hormone-induced transcriptional activation of the thyrotropin β gene. . 2011. PMID 21533184 · DOI · PMC3077393
  4. Constantinescu A, Chandrasekar A, Kleindienst L, Höhne L, Da Silva Lima N, Richter M, et al.. Thyrotropin-releasing hormone neurons of different hypothalamic nuclei increase energy expenditure. . 2026. PMID 41980928 · DOI · PMC13083850
  5. Fliers E, Bianco AC, Langouche L, Boelen A. Thyroid function in critically ill patients. Lancet Diabetes Endocrinol. 2015. PMID 26071885 · DOI · PMC4979220
  6. Jackson IM. Thyrotropin-releasing hormone. N Engl J Med. 1982. PMID 6798440 · DOI
  7. Lechan RM, Fekete C. The TRH neuron: a hypothalamic integrator of energy metabolism. Prog Brain Res. 2006. PMID 16876577 · DOI
  8. Fekete C, Lechan RM. Central regulation of hypothalamic-pituitary-thyroid axis under physiological and pathophysiological conditions. Endocr Rev. 2014. PMID 24423980 · DOI · PMC3963261
  9. Morley JE. The neuroendocrine control of appetite: the role of the endogenous opiates, cholecystokinin, TRH, gamma-amino-butyric-acid and the diazepam receptor. Life Sci. 1980. PMID 6774182 · DOI
  10. Chiamolera MI, Wondisford FE. Minireview: Thyrotropin-releasing hormone and the thyroid hormone feedback mechanism. Endocrinology. 2009. PMID 19179434 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-31.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • Gonadotropin-Releasing HormoneDrugs and Chemicals
  • LeuprolideDrugs and Chemicals
  • Angiotensin IDrugs and Chemicals
  • Angiotensin IIDrugs and Chemicals
  • Arginine VasopressinDrugs and Chemicals
  • Corticotropin-Releasing HormoneDrugs and Chemicals

All 546 articles in Drugs and Chemicals →

At a glance

12,941
PubMed records on this heading
1%
published since 2020
921
review articles
169
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • Gonadotropin-Releasing HormoneDrugs and Chemicals
  • LeuprolideDrugs and Chemicals
  • Angiotensin IDrugs and Chemicals
  • Angiotensin IIDrugs and Chemicals
  • Arginine VasopressinDrugs and Chemicals

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support